Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Biosimilars
Generic and Biosimilar Drugs Generate $408 Billion in Savings for America’s Patients and Healthcare System in 2022
Biosimilars
October 2023, Vol 14, No 5
Washington, DC—On September 6, 2023, the Association for Accessible Medicines (AAM), the leading trade association for generic and biosimilar manufacturers, released its 2023
U.S. Generic & Biosimilar Medicines Savings Report
highlighting the value of generic and biosimilar medicines.
Read Article
Survey Results Provide Insights into Biosimilar Use at Cancer Centers
By
Wayne Kuznar
Biosimilars
,
ASCO 2022 Highlights
February 2023, Vol 14, No 1
Results from a survey of cancer centers revealed that 66% of responding institutions had a biosimilar interchangeability policy in place, but barriers to adoption remain an issue.
Read Article
Results from Phase 3 Trial Show Similar Efficacy and Safety Outcomes with CT-P16 versus Bevacizumab in Patients with NSCLC
Biosimilars
Web Exclusives
One-year follow-up data from a phase 3 study found similar duration of response, time to progression (TTP), and survival rates with the biosimilar candidate CT-P16 compared with its reference drug, bevacizumab (Avastin), in the first-line treatment of patients with metastatic or recurrent nonsquamous non–small-cell lung cancer (NSCLC).
Read Article
Biosimilar Substitution May Reduce Financial Risk to Providers in Value-Based Payment Models
By
Wayne Kuznar
Biosimilars
,
ASCO 2022 Highlights
February 2023, Vol 14, No 1
Providers participating in the Centers for Medicare & Medicaid Services’ (CMS’) value-based payment (VBP) models may realize a reduction in financial risk via biosimilar substitution.
Read Article
Survey Reveals Physicians’ Attitudes Toward Biosimilars
By
Phoebe Starr
Biosimilars
December 2022, Vol 13, No 6
A survey of US physicians who prescribe biologics to their patients revealed that 92% were confident in the safety and efficacy of biosimilars, 89% would prescribe a biosimilar to a new patient, and 80% were comfortable initiating the switching of patients who are stable on their current biologic medication to a biosimilar. However, the majority of respondents indicated that they were not comfortable with third-party substitution for nonmedical reasons, and felt that they, along with their patients, should have control over treatment choice. Results of this survey were discussed by Ralph McKibbin, MD, FACP, FACG, AGAF, Chairman of the Alliance for Safe Biologic Medicines, in a poster presentation during the Drug Information Association 2022 Global Annual Meeting.
Read Article
Increased Biosimilar Use Translates to Substantial Savings for Oncology Practices
By
Wayne Kuznar
Biosimilars
October 2022, Vol 13, No 5
The increased use of biosimilars within the US Oncology Network generated more than $6 million of savings in the Centers for Medicare & Medicaid Services’ Oncology Care Model (OCM) during the first half of 2020.
Read Article
Survey of Oncologists Identifies Several Misconceptions Regarding Biosimilars
By
Chase Doyle
Biosimilars
April 2022, Vol 13, No 2
Adoption of biosimilars continues to rise in the United States, but oncologists’ knowledge regarding these agents has not kept pace, according to data presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium.
Read Article
Analysis of Insurance Claims Reveals Upward Trend in the Use of Trastuzumab Biosimilars
By
Chase Doyle
Biosimilars
April 2022, Vol 13, No 2
The development of biosimilar medicines has provided an opportunity for patient utilization of oncology treatments at a lower cost, particularly in individuals for whom biologicals play a predominant role in providing effective therapeutic and supportive care.
Read Article
Pharmacist-Driven Intervention Leads to Significant Increase in Biosimilar Adoption
By
Chase Doyle
Biosimilars
February 2022, Vol 13, No 1 Online Only
Rapid adoption of FDA-approved biosimilars is feasible, measurable, and scalable—and pharmacists should lead the charge, according to data presented at the virtual 2021 American Society of Clinical Oncology Quality Care Symposium.
Read Article
Rapid Biosimilar Adoption Possible in Community Oncology Practice
By
Chase Doyle
ASCO 2021 Highlights
,
Biosimilars
August 2021, Vol 12, No 4
Biosimilars have the potential to create a more sustainable healthcare environment by offering substantial cost-savings and expanding patient access to lifesaving therapies. At the ASCO 2021 virtual annual meeting, Lalan S. Wilfong, MD, Executive Vice President, Value-Based Care and Quality Programs, and Medical Oncologist/Hematologist, Texas Oncology, Presbyterian Cancer Center Dallas, TX, discussed how a community practice model for therapeutic interchange of brand drugs to biosimilars led to a significant increase in utilization of biosimilars and substantial cost-savings over the course of a single year at his institution.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma